FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds

AdComBPC-157Positive

AI Analysis

Summary

An FDA Advisory Panel voted 8-6-1 in July 2026 to recommend BPC-157 for inclusion in the 503A Bulks List, though the recommendation is non-binding and does not constitute FDA approval. FDA staff had opposed the inclusion, and a 2025 systematic review identified 35 preclinical studies and one clinical study relevant to the consideration.

Outcome Details

FDA Advisory Panel voted 8-6-1 to back BPC-157 for 503A Bulks List inclusion in July 2026; recommendation is non-binding and does not constitute FDA approval; FDA staff proposed against inclusion

Importance:5/10

Sentiment:

0.30

FDA Advisory PanelBPC-157503A BulksNon-binding RecommendationRegulatory

Read the original article

Published by PR Newswire Biotech on September 8, 2026 6:34 PM

Read Original